EMA Authorised: Hizentra (human normal immunoglobulin (SCIg)) — CSL Behring GmbH

View source ↗

Summary

EMA authorised Hizentra, a subcutaneous immunoglobulin product, by CSL Behring, for immunologic deficiency syndromes related to primary immunodeficiency in the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Status: Authorised. Therapeutic area: Immunologic Deficiency Syndromes. MAH: CSL Behring GmbH. Decision date: 25/09/2025